The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 /PRNewswire/ ...

Procedural flexibility incorporated into many cancer clinical trials during the COVID-19 pandemic had no long-term negative ...

Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single ...

Nations that lead in clinical trials get earlier access to breakthrough therapies, shape global regulatory norms, and ...

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

Decentralized Clinical Trials (DCTs) are transforming how we collect clinical data, but this evolution brings unprecedented challenges in data quality, complexity, and integration.

Phase 3 trial clearance is based on the Phase 1/2 results demonstrating safety and efficacy of the 3x10¹³ vg/kg dose of microdystrophin, which is lower than doses used in other gene therapies for ...

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.